S
Shi-Ming Lin
Researcher at Memorial Hospital of South Bend
Publications - 124
Citations - 6621
Shi-Ming Lin is an academic researcher from Memorial Hospital of South Bend. The author has contributed to research in topics: Hepatocellular carcinoma & Hepatitis B. The author has an hindex of 35, co-authored 112 publications receiving 5946 citations. Previous affiliations of Shi-Ming Lin include Chang Gung University.
Papers
More filters
Journal ArticleDOI
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.
Masao Omata,Laurentius A. Lesmana,Ryosuke Tateishi,Pei-Jer Chen,Shi-Ming Lin,Haruhiko Yoshida,Masatoshi Kudo,Jeong Min Lee,Byung Ihn Choi,Ronnie T.P. Poon,Shuichiro Shiina,Ann-Lii Cheng,Ji Dong Jia,Shuntaro Obi,Kwang Hyub Han,Wasim Jafri,Pierce K. H. Chow,Seng Gee Lim,Yogesh Chawla,Unggul Budihusodo,Rino Alvani Gani,C. Rinaldi A. Lesmana,Terawan Agus Putranto,Yun Fan Liaw,Shiv Kumar Sarin +24 more
TL;DR: Recommendations on the management of hepatocellular carcinoma were presented at the fourth APASL single topic conference on viral-related HCC at Bali, Indonesia and approved by the participants of the conference.
Journal ArticleDOI
Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤4 cm
TL;DR: RF ablation yielded better clinical outcomes than conventional and higher-dose PEI in treating HCC 4 cm or less andMultivariate analysis determined that tumor size, tumor differentiation, and the method of treatment (RF vs both methods of PEI) were significant factors in relation to local tumor progression, overall survival, and cancer-free survival.
Journal ArticleDOI
Long‐term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection
TL;DR: Multivariate analysis showed that IFN therapy, preexisting cirrhosis, and the patient's age at entry are significant independent factors for both survival and HCC development.
Journal ArticleDOI
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma
Shi-Ming Lin,Ming-Lung Yu,Chuan-Mo Lee,Rong-Nan Chien,I-Shyan Sheen,Chia-Ming Chu,Yun-Fan Liaw +6 more
TL;DR: Multivariate analysis showed that IFN therapy, HBeAg seroconversion and genotype B HBV infection are independent factors for better long-term outcomes.
Journal ArticleDOI
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial
Masatoshi Kudo,Guohong Han,Richard S. Finn,Ronnie T.P. Poon,Jean-Frédéric Blanc,Lunan Yan,Jijin Yang,Ligong Lu,Won Young Tak,Xiaoping Yu,Joon-Hyeok Lee,Shi-Ming Lin,Changping Wu,Tawesak Tanwandee,Guoliang Shao,Ian Walters,Christine Dela Cruz,Valerie Poulart,Jianhua Wang +18 more
TL;DR: In this study, brivanib as adjuvant therapy to TACE did not improve OS and the trial was terminated after randomization of 502 patients when two other phase III studies of Brivanib in advanced HCC patients failed to meet OS objectives.